Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Stopped The trial was intended to be a Phase 1/2 trial (but the trial never moved forward to Phase 2).

Conditions

• Metastatic Castration Resistant Prostate Cancer

Interventions

• BIOLOGICAL: LAVA-1207
• BIOLOGICAL: LAVA-1207 plus Pembrolizumab

Sponsor

Lava Therapeutics

Collaborators

• [object Object]